Loading patent…
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsJohn F. McDyer, Iulia-Dana Popescu, Akihiko Hoji
Estimating the term…
This document relates to methods and materials involved in identifying and/or treating mammals having a CMV infection. For example, methods and materials for assessing a mammal having a CMV infection (e.g., a CMV seronegative human who received CMV seropositive donor transplant tissue) to determine if the mammal is likely to control the CMV infection or to determine if the mammal is unlikely to control the CMV infection are provided. Methods and materials for treating a mammal having a CMV infection (e.g., a CMV seronegative human who received CMV seropositive donor transplant tissue) that was either identified as being likely to control the CMV infection or identified as being unlikely to control the CMV infection also are provided.
1-31. (canceled)
A method for treating a CMV infection, wherein said method comprises administering, to a mammal (a) having said CMV infection and (b) identified as lacking an elevated level of KLRG1+/CD8+ T cells, an antiviral agent.
37-39. (canceled)
(canceled)
A method for treating a CMV infection, wherein said method comprises:
48-51. (canceled)
A method for monitoring a CMV infection in a manner that avoids the need to administer an antiviral agent to a mammal having said CMV infection, wherein said method comprises assessing a symptom of said CMV infection in said mammal and avoiding administration of an antiviral agent to said mammal, wherein said mammal was identified as having a moderately elevated or highly elevated level of KLRG1+/CD8+ T cells.
62-72. (canceled)
Dependencies are inferred from the claim text.